| Name | Title | Contact Details |
|---|
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
Bionest Partners is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife
Biothera is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Unlocking the secrets of life itself is the driving force behind the Salk Institute. Our team of world-class, award-winning scientists pushes the boundaries of knowledge in areas such as neuroscience, cancer research, aging, immunobiology, plant biology, computational biology, and more. Founded by Jonas Salk, developer of the first safe and effective polio vaccine, the Institute is an independent, nonprofit research organization and architectural landmark: small by choice, intimate by nature, and fearless in the face of any challenge.